Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
Clinical trial NCT06096116 · RECRUITING
Trial details
- NCT number
- NCT06096116
- Sponsor
- Octapharma
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-21
- Primary completion
- 2028-03-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.